[New anticoagulants - direct thrombin inhibitors]

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Hematology

Background:

• Direct thrombin inhibitors (DTIs) inactivate both free and fibrin-bound thrombin.
• Parenteral DTIs include lepirudin, desirudin, bivalirudin, and argatroban, all safe for heparin-induced thrombocytopenia (HIT).
• Oral DTIs like dabigatran etexilate offer predictable anticoagulation without routine monitoring.

Purpose of the Study:

• To review the properties and clinical applications of direct thrombin inhibitors, focusing on dabigatran etexilate.
• To compare the efficacy and safety of dabigatran etexilate with existing treatments and emerging factor Xa inhibitors.

Main Methods:

• Review of clinical studies and pharmacological data on direct thrombin inhibitors.
• Analysis of safety, efficacy, pharmacokinetics, and drug interactions of dabigatran etexilate.
• Comparison with standard anticoagulants and direct factor Xa inhibitors.

Main Results:

• Dabigatran etexilate demonstrated non-inferiority for stroke prevention in atrial fibrillation, venous thromboembolism prophylaxis, and treatment.
• The oral prodrug dabigatran etexilate is converted to active dabigatran, primarily renally eliminated.
• Few drug interactions exist, but p-glycoprotein inhibitors can significantly increase dabigatran plasma levels.

Conclusions:

• Dabigatran etexilate is an effective and convenient oral anticoagulant for several indications.
• Its predictable profile allows for use without dose adjustment or monitoring.
• Head-to-head comparisons with direct factor Xa inhibitors are needed to determine definitive advantages.